Project Grant R01CA315082
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $593K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60611, USA
Similar Awards
- The National Cancer Institute (a component of the Department of Health and Human Services National Institutes of Health) awarded Northwestern University $1,431,654 on September 23, 2025, under the Cancer Biology Research program (CFDA 93.396) to investigate how leukemia stem cell persistence during tyrosine kinase inhibitor treatment in chronic myeloid leukemia is influenced by interaction with CD8+ T cells. The research will employ single-cell RNA sequencing and murine transplant models to...
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded the University of Illinois $422,649 as a Project Grant (R21CA303745) on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396). The award funds research into racial disparities in acute myeloid leukemia (AML) treatment outcomes. The study examines whether NPM1 mutant status determines FOXM1 cytoplasmic localization and inactivation in primary bone marrow samples from Black AML...
- The National Cancer Institute awarded the University of Chicago $547,740 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to define the molecular mechanisms by which the MLL1 histone modification complex and the long noncoding RNA HOTTIP interact in acute myeloid leukemia pathogenesis. The research examines whether non-specific RNA binding to the WDR5 subunit of the MLL1 complex inhibits the complex's histone methyltransferase activity and whether the RBBP5...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $2,970,010 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on September 16, 2025, with completion targeted for August 31, 2029. The research initiative focuses on elucidating the tumorigenic mechanisms of somatic truncation mutations in KMT2D, which encodes the histone methyltransferase MLL4 (mixed-lineage leukemia 4), particularly as...
- The National Cancer Institute awarded Northwestern University a $1.139 million Cooperative Agreement (UG1CA308665) on April 28, 2026, under the Cancer Treatment Research program (CFDA 93.395) to serve as a Lead Academic Participating Site within the NCI National Clinical Trials Network. The Robert H. Lurie Comprehensive Cancer Center at Northwestern will drive innovation in cancer clinical trials, particularly early-phase and multi-center studies, while expanding access to treatments across...
- The National Cancer Institute awarded Northwestern University $631,487 under the Cancer Cause and Prevention Research program (CFDA 93.393) on June 1, 2026, to conduct mechanistic research on LKB1-mutant lung cancer and therapeutic resistance. The research combines genomics and mass spectrometry approaches with lung cancer cell lines and mouse models to determine how LKB1 loss regulates HDAC3/NKX2-1 complex function, to test whether LKB1 status predicts response to combined KRAS pathway...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded Albert Einstein College of Medicine $431,970 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to investigate combination approaches to acute myeloid leukemia targeting both CD123-directed NK cell engagers and BCL-2 inhibition through venetoclax. The research will employ dynamic BH3 profiling to probe mitochondrial priming mechanisms and test whether...
- The National Cancer Institute awarded The Washington University Office of Sponsored Research Services $643,286 on August 1, 2026, to investigate DNA methylation epimutations in acute myeloid leukemia under the Cancer Biology Research program (CFDA 93.396). The research investigates allele-specific DNA methylation epimutations as clonal events that arise in normal cells and may be selected for during leukemogenesis. The project uses primary human acute myeloid leukemia samples, normal...
- The National Cancer Institute awarded the University of Wisconsin - Madison $699,587 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to characterize the molecular mechanisms by which MLL-partial tandem duplication (MLLPTD) drives acute myeloid leukemia and myelodysplastic syndromes. The project leverages targeted mass spectrometry and newly developed antibodies to define how allelic complexity modifies MLLPTD protein interactions, chromatin binding, and gene regulatory...
- The National Cancer Institute awarded The Johns Hopkins University $218,089 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test engineered natural killer cell therapy targeting acute myeloid leukemia. The funded work develops chimeric cytokine receptor (CCR)-engineered NK cells designed to attack AML-associated surface antigens and overcome AML-mediated NK cell suppression. In Aim 1, the recipient will engineer NK cells to express dual interleukin...